PDF
ePub
Citation
Print
Abstract
Recurrent urinary tract infection is a common infectious disease seen in the clinic. It is very prevalent in women; as many as 15% of women develop urinary tract infection each year, and at least 25% have one or more recurrences. Chronic inflammation and increased urothelial apoptosis reflect a common pathophysiology in various lower urinary tract dysfunctions, causing bladder storage symptoms. It has been suggested that chronic inflammation could be associated with overactive detrusor and increased levels of urinary nerve growth factor and creatinine. The level of urinary nerve growth factor may decrease after an effective antimuscarinic therapy. Recurrent urinary tract infection could be prevented by using nonsteroidal anti-inflammatory drugs or cyclooxygenase-2 inhibitors. Intravesical hyaluronate and chondroitin sulfate reduce the incidence of recurrent bacterial cystitis, and treatment with hyaluronate targets bacterial adherence to the bladder mucosa in interstitial cystitis/bladder pain syndrome. This article reviews the pathophysiology of chronic inflammation of the bladder and investigates the association between chronic inflammation and recurrent urinary tract infection.
REFERENCES
1.Choe HS., Lee SJ. National trends of antimicrobial resistance in uncomplicated cystitis. Urogenit Tract Infect. 2016. 11:7–11.
2.Grover S., Srivastava A., Lee R., Tewari AK., Te AE. Role of inflammation in bladder function and interstitial cystitis. Ther Adv Urol. 2011. 3:19–33.
3.Liu HT., Jiang YH., Kuo HC. Alteration of urothelial Inflammation, apoptosis, and junction protein in patients with various bladder conditions and storage bladder symptoms suggest common pathway involved in underlying pathophysiology. Low Urin Tract Symptoms. 2015. 7:102–7.
4.Liu HT., Jiang YH., Kuo HC. Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy. PLoS One. 2013. 8:e76706.
5.Tyagi P., Barclay D., Zamora R., Yoshimura N., Peters K., Vodovotz Y, et al. Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol. 2010. 42:629–35.
6.Hooton TM. Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection. Int J Antimicrob Agents. 2003. 22(Suppl 2):65–72.
7.Fihn SD. Clinical practice. Acute uncomplicated urinary tract infection in women. N Engl J Med. 2003. 349:259–66.
8.Foxman B., Barlow R., D'Arcy H., Gillespie B., Sobel JD. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000. 10:509–15.
9.Car J. Urinary tract infections in women: diagnosis and management in primary care. BMJ. 2006. 332:94–7.
10.Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002. 113(Suppl 1A):5S-13S.
11.Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon. 2003. 49:53–70.
12.Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010. 7:653–60.
13.Arya LA., Northington GM., Asfaw T., Harvie H., Malykhina A. Evidence of bladder oversensitivity in the absence of an infection in premenopausal women with a history of recurrent urinary tract infections. BJU Int. 2012. 110:247–51.
14.Birder L., Andersson KE. Urothelial signaling. Physiol Rev. 2013. 93:653–80.
15.Liu HT., Chancellor MB., Kuo HC. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol. 2009. 56:700–6.
16.Liu HT., Chen CY., Kuo HC. Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders. J Formos Med Assoc. 2010. 109:862–78.
17.Chan CY., St John AL., Abraham SN. Mast cell interleukin-10 drives localized tolerance in chronic bladder infection. Immunity. 2013. 38:349–59.
18.Ratner JJ., Thomas VL., Sanford BA., Forland M. Bacteria-specific antibody in the urine of patients with acute pyelonephritis and cystitis. J Infect Dis. 1981. 143:404–12.
19.Rene P., Silverblatt FJ. Serological response to Escherichia coli pili in pyelonephritis. Infect Immun. 1982. 37:749–54.
20.Sant GR., Kempuraj D., Marchand JE., Theoharides TC. The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology. 2007. 69(4 Suppl):34–40.
21.Khasriya R., Sathiananthamoorthy S., Ismail S., Kelsey M., Wilson M., Rohn JL, et al. Spectrum of bacterial colonization associated with urothelial cells from patients with chronic lower urinary tract symptoms. J Clin Microbiol. 2013. 51:2054–62.
22.Sorrentino F., Cartwright R., Digesu GA., Tolton L., Franklin L., Singh A, et al. Associations between individual lower urinary tract symptoms and bacteriuria in random urine samples in women. Neurourol Urodyn. 2015. 34:429–33.
23.Balachandran AA., Wildman SS., Strutt M., Duckett J. Is chronic urinary infection a cause of overactive bladder? Eur J Obstet Gynecol Reprod Biol. 2016. 201:108–12.
24.Hannan TJ., Roberts PL., Riehl TE., van der Post S., Binkley JM., Schwartz DJ, et al. Inhibition of cyclooxygenase-2 prevents chronic and recurrent cystitis. EBioMedicine. 2014. 1:46–57.
25.Hannan TJ., Mysorekar IU., Hung CS., Isaacson-Schmid ML., Hultgren SJ. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog. 2010. 6:e1001042.
26.Schlager TA., LeGallo R., Innes D., Hendley JO., Peters CA. B cell infiltration and lymphonodular hyperplasia in bladder submucosa of patients with persistent bacteriuria and recurrent urinary tract infections. J Urol. 2011. 186:2359–64.
27.Jang J., Park EY., Seo SI., Hwang TK., Kim JC. Effects of intravesical instillation of cyclooxygenase-2 inhibitor on the expression of inducible nitric oxide synthase and nerve growth factor in cyclophosphamide-induced overactive bladder. BJU Int. 2006. 98:435–9.
28.Vizzard MA. Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. Exp Neurol. 2000. 161:273–84.
29.Yoshimura N. Bladder afferent pathway and spinal cord injury: possible mechanisms inducing hyperreflexia of the urinary bladder. Prog Neurobiol. 1999. 57:583–606.
30.Liu HT., Kuo HC. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. Urology. 2008. 72:104–8. discussion 108.
31.Lowe EM., Anand P., Terenghi G., Williams-Chestnut RE., Sinicropi DV., Osborne JL. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol. 1997. 79:572–7.
32.Liu HT., Kuo HC. Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol. 2008. 179:2270–4.
33.Liu HT., Chancellor MB., Kuo HC. Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. BJU Int. 2008. 102:1440–4.
34.Kuo HC., Liu HT., Tyagi P., Chancellor MB. Urinary nerve growth factor levels in urinary tract diseases with or without frequency urgency symptoms. Low Urin Tract Symptoms. 2010. 2:88–94.
35.Gupta K., Bhadelia N. Management of urinary tract infections from multidrug-resistant organisms. Infect Dis Clin North Am. 2014. 28:49–59.
36.Ikäheimo R., Siitonen A., Heiskanen T., Karkkainen U., Kuos-manen P., Lipponen P, et al. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis. 1996. 22:91–9.
37.Mysorekar IU., Hultgren SJ. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc Natl Acad Sci U S A. 2006. 103:14170–5.
38.Mulvey MA., Schilling JD., Hultgren SJ. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun. 2001. 69:4572–9.
39.Poggi MM., Johnstone PA., Conner RJ. Glycosaminoglycan content of human bladders: a method of analysis using cold-cup biopsies. Urol Oncol. 2000. 5:234–7.
40.Constantinides C., Manousakas T., Nikolopoulos P., Stanitsas A., Haritopoulos K., Giannopoulos A. Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study. BJU Int. 2004. 93:1262–6.
41.Stav K., Lindner A. Interstitial cystitis/painful bladder syndrome: a comprehensive review of the current literature. Harefuah. 2011. 150:168–74.
42.Hurst RE., Rhodes SW., Adamson PB., Parsons CL., Roy JB. Functional and structural characteristics of the glycosaminoglycans of the bladder luminal surface. J Urol. 1987. 138:433–7.
43.Raymond I., Vasdev N., Ferguson J., Haskin M., Davis L., Hasan TS. The clinical effectiveness of intravesical sodium hyaluronate (cystistatⓇ) in patients with interstitial cystitis/painful bladder syndrome and recurrent urinary tract infections. Curr Urol. 2012. 6:93–8.
44.De Vita D., Giordano S. Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study. Int Urogynecol J. 2012. 23:1707–13.
45.Damiano R., Quarto G., Bava I., Ucciero G., De Domenico R., Palumbo MI, et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol. 2011. 59:645–51.
46.Amdekar S., Singh V., Singh DD. Probiotic therapy: immunomo-dulating approach toward urinary tract infection. Curr Microbiol. 2011. 63:484–90.
47.Stapleton AE., Au-Yeung M., Hooton TM., Fredricks DN., Roberts PL., Czaja CA, et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis. 2011. 52:1212–7.
48.Jepson RG., Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2008. 1:CD001321.
49.Schwenger EM., Tejani AM., Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst Rev. 2015. 12:CD008772.
50.Jepson RG., Williams G., Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012. 10:CD001321.
51.Takahashi S., Hamasuna R., Yasuda M., Arakawa S., Tanaka K., Ishikawa K, et al. A randomized clinical trial to evaluate the preventive effect of cranberry juice (UR65) for patients with recurrent urinary tract infection. J Infect Chemother. 2013. 19:112–7.
52.Jepson R., Craig J., Williams G. Cranberry products and prevention of urinary tract infections. JAMA. 2013. 310:1395–6.
53.Schmidhammer S., Ramoner R., Holtl L., Bartsch G., Thurnher M., Zelle-Rieser C. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. Urology. 2002. 60:521–6.
54.Bauer HW., Alloussi S., Egger G., Blumlein HM., Cozma G., Schulman CC. Multicenter UTI Study Group. A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol. 2005. 47:542–8. discussion 548.
55.Tammen H. The German Urinary Tract Infection Study Group. Immunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. Br J Urol. 1990. 65:6–9.
56.Chiavaroli C., Moore A. An hypothesis to link the opposing immunological effects induced by the bacterial lysate OM-89 in urinary tract infection and rheumatoid arthritis. BioDrugs. 2006. 20:141–9.
57.Schulman CC., Corbusier A., Michiels H., Taenzer HJ. Oral immunotherapy of recurrent urinary tract infections: a double-blind placebo-controlled multicenter study. J Urol. 1993. 150:917–21.
58.Magasi P., Panovics J., Illes A., Nagy M. Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial. Eur Urol. 1994. 26:137–40.
XML Download